Barclays’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.78M | Buy |
152,770
+133,500
| +693% | +$4.18M | ﹤0.01% | 1661 |
|
|
2025
Q1 | $646K | Buy |
19,270
+1,143
| +6% | +$38.3K | ﹤0.01% | 2694 |
|
|
2024
Q4 | $711K | Buy |
18,127
+3,134
| +21% | +$123K | ﹤0.01% | 2844 |
|
|
2024
Q3 | $590K | Buy |
14,993
+13,903
| +1,276% | +$547K | ﹤0.01% | 2903 |
|
|
2024
Q2 | $42K | Sell |
1,090
-11,464
| -91% | -$442K | ﹤0.01% | 3743 |
|
|
2024
Q1 | $540K | Sell |
12,554
-99,436
| -89% | -$4.28M | ﹤0.01% | 2787 |
|
|
2023
Q4 | $5.16M | Buy |
111,990
+102,469
| +1,076% | +$4.72M | ﹤0.01% | 1465 |
|
|
2023
Q3 | $324K | Buy |
9,521
+342
| +4% | +$11.6K | ﹤0.01% | 2792 |
|
|
2023
Q2 | $354K | Buy |
9,179
+9,079
| +9,079% | +$350K | ﹤0.01% | 2798 |
|
|
2023
Q1 | $4K | Buy |
+100
| New | +$4K | ﹤0.01% | 4186 |
|
|
2022
Q2 | – | Sell |
-191
| Closed | -$6K | – | 4942 |
|
|
2022
Q1 | $6K | Buy |
+191
| New | +$6K | ﹤0.01% | 4569 |
|
|
2021
Q3 | – | Sell |
-40
| Closed | -$1K | – | 4179 |
|
|
2021
Q2 | $1K | Sell |
40
-142
| -78% | -$3.55K | ﹤0.01% | 4055 |
|
|
2021
Q1 | $3K | Buy |
182
+96
| +112% | +$1.58K | ﹤0.01% | 3809 |
|
|
2020
Q4 | $1K | Buy |
+86
| New | +$1K | ﹤0.01% | 3507 |
|
|
2020
Q1 | – | Sell |
-163
| Closed | -$2K | – | 3948 |
|
|
2019
Q4 | $2K | Sell |
163
-217
| -57% | -$2.66K | ﹤0.01% | 3798 |
|
|
2019
Q3 | $3K | Buy |
+380
| New | +$3K | ﹤0.01% | 3986 |
|
|
2019
Q2 | – | Sell |
-2
| Closed | – | – | 4461 |
|
|
2019
Q1 | $0 | Sell |
2
-3,725
| -100% | – | ﹤0.01% | 4432 |
|
|
2018
Q4 | $24K | Buy |
+3,727
| New | +$24K | ﹤0.01% | 3341 |
|